Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

Similar articles for PubMed (Select 15634273)

1.

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P; BISTRO II Study Group.

J Thromb Haemost. 2005 Jan;3(1):103-11.

PMID:
15634273
2.

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V.

J Thromb Haemost. 2004 Sep;2(9):1573-80.

PMID:
15333033
3.

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group.

Lancet. 2007 Sep 15;370(9591):949-56. Erratum in: Lancet. 2007 Dec 15;370(9604):2004.

PMID:
17869635
4.

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group.

J Thromb Haemost. 2007 Nov;5(11):2178-85.

PMID:
17764540
5.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
6.

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.

Thromb Res. 2010 Sep;126(3):175-82. doi: 10.1016/j.thromres.2010.03.021. Epub 2010 May 15.

PMID:
20434759
7.

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA.

J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14.

PMID:
18534438
8.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
9.

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.

Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW.

J Thromb Haemost. 2003 Oct;1(10):2119-30.

PMID:
14521593
10.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

PMID:
19243718
11.

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI.

Thromb Haemost. 2009 Jan;101(1):77-85.

PMID:
19132192
12.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

13.

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.

Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A; EXPRESS Study Group.

J Thromb Haemost. 2003 Dec;1(12):2490-6.

PMID:
14675083
14.
15.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Eriksson BI, Friedman RJ.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31. Review.

PMID:
19648146
16.

A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.

Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT.

J Thromb Haemost. 2007 Apr;5(4):746-53.

PMID:
17408408
17.

Dabigatran: new drug. Continue to use heparin, a better-known option.

[No authors listed]

Prescrire Int. 2009 Jun;18(101):97-9.

PMID:
19637411
18.

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.

Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D; Melagatran for Thrombin inhibition in Orthopaedic surgery.

Lancet. 2002 Nov 9;360(9344):1441-7.

PMID:
12433510
19.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Pharmacoeconomics. 2012 Feb 1;30(2):137-46. doi: 10.2165/11591590-000000000-00000. Review.

PMID:
22185183
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk